News Analysis
The Latest
We Have a Cure for Hepatitis C. Why Are Rates So High?
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Trends in Deaths Among People With Hepatitis C Virus in British Columbia
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
IAS 2019: What to Expect in HIV Science
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
CROI 2019: What News to Expect in HIV Science and Policy
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Dual Maintenance Therapy With Dolutegravir + Rilpivirine
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.
Sofosbuvir Access: New Patent Challenges to Sofosbuvir
The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.
International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014
An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...
Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug
HCV drugs are priced out of reach and out of control.
-- Michel Sidibé, UNAIDS
MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...
How Will New Hepatitis C Drug Pricing Affect Health Care Costs?
It’s been a breakthrough year for hepatitis C treatment, but that breakthrough has come with a price tag that has stirred considerable debate. We take a closer look at how hep C drug pricing could impact future health care costs.